The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
Published at www.nejm.org November 15, 2009 (10.1056/NEJMe0910677)

Cangrelor — A Champion Lost in Translation?
Adnan Kastrati, M.D., and Gjin Ndrepepa, M.D.

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-Disclosures
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Current guidelines recommend the early use of drugs that block platelet adenosine diphosphate (ADP) receptor P2Y12 in patients with acute coronary syndromes in whom percutaneous coronary intervention (PCI) may be performed.1 PCI is ultimately performed in 60 to 70% of patients with acute coronary syndromes who undergo diagnostic coronary angiography.2,3 The remaining patients are treated either medically or with urgent coronary-artery bypass grafting (CABG). An ideal ADP-receptor antagonist has to be potent and have a rapid onset and offset of antiplatelet action. The thienopyridines, clopidogrel and prasugrel, are ADP-receptor antagonists that have been approved by the Food and Drug Administration . . . [Full Text of this Article]


Source Information

From Deutsches Herzzentrum, Technische Universität München, Munich, Germany.

This article (10.1056/NEJMe0910677) was published on November 15, 2009, at NEJM.org.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2010 Massachusetts Medical Society. All rights reserved.